Business Context and Reporting Period
This Form 8-K Current Report was filed by ENDRA Life Sciences Inc. on January 5, 2022. The Company is incorporated in Delaware and its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols NDRA and NDRAW, respectively. The filing primarily addresses a regulatory notification regarding the Company's continued listing status.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and listing compliance rather than financial performance data.
Material Changes and Listing Status
On January 5, 2022, the Company received a notification from Nasdaq stating that its common stock no longer meets the Minimum Bid Price Requirement under Nasdaq Marketplace Rule 5550(a)(2). The deficiency occurred because the closing bid price remained below $1.00 for 30 consecutive trading days. The notification has no immediate effect on the listing.
Outlook, Compliance Timeline, and Risks
- Compliance Period: The Company has 180 calendar days, until July 5, 2022, to regain compliance.
- Compliance Criteria: To cure the deficiency, the bid price must close at or above $1.00 per share for a minimum of 10 consecutive business days before July 5, 2022.
- Secondary Compliance Option: If the Company fails to meet the bid price requirement by the initial deadline, it may be eligible for an additional 180-day period. This requires meeting the market value of publicly held shares and other initial listing standards, potentially necessitating a reverse stock split.
- Delisting Risk: If the Company cannot cure the deficiency or is deemed ineligible for an extension, Nasdaq may delist the securities. The Company may appeal such a determination, though approval is not guaranteed.
- Management Action: The Company intends to actively monitor the bid price and consider available options to resolve the deficiency.
Additionally, under Item 7.01, the Company disclosed an updated investor presentation posted on its website on January 7, 2022, which is furnished as Exhibit 99.1.
Investor Verification Checklist
- Verify the current closing bid price of NDRA to assess progress toward the $1.00 threshold.
- Monitor the Company's announcements regarding a potential reverse stock split if the initial compliance period expires without success.
- Review the updated investor presentation (Exhibit 99.1) for any new strategic updates or financial guidance not included in this 8-K.
- Track the July 5, 2022 deadline for the initial compliance period.